The impact of COVID-19 vaccine reactions on secondary vaccine hesitancy

Freeman, Esther E.; Strahan, Alexis G.; Smith, Liam R.; Judd, Allen D.; Samarakoon, Upeka; Chen, Geoffrey; King, Andrew J.; Blumenthal, Kimberly G.

doi:10.1016/j.anai.2024.01.009

Cited by 4 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is especially relevant as most people in the US and Canada have received a primary series of an mRNA vaccine. Concern about side effects is a primary reason for COVID-19 vaccine hesitancy [22-24]. Accordingly, COVID-19 vaccines with lower rates of reactogenicity, which is suggested of heterologous use of NVX-CoV2373 by the present analysis and several descriptive studies [12,25,26,30], have the potential to decrease vaccine hesitancy.…”

Section: Discussionmentioning

confidence: 94%

“…Of note, studies comparing reactogenicity have generally found a higher incidence of local and systemic events following receipt of mRNA COVID-19 vaccines compared with influenza and other non-COVID-19 vaccines, as well as a higher frequency of reactogenicity-associated medication use, sick leave, and doctor's visits [15,16]. COVID-19 vaccine-related reactogenicity events can affect work and other daily activities, leading to absenteeism from work [17,18] and presenteeism [17,19], as well as vaccine hesitancy [20][21][22][23][24]. Indeed, concern over vaccine side effects was found to be the most common reason for refusing an updated COVID-19 vaccine [24].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reactogenicity Differences between COVID-19 Vaccines: A Pro-spective Observational Study in the United States and Canada

Rousculp,

Hollis,

Ziemiecki

et al. 2024

Preprint

View full text Add to dashboard Cite

Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side effects may lead to reluctance to receive updated COVID-19 vaccinations. A real-world, post hoc analysis, observational 2019nCoV-406 study, was conducted to examine reactogenicity within the first 2 days after vaccination with either a protein-based vaccine (NVX-CoV2373) or an mRNA vaccine (BNT162b2 or mRNA-1273) in individuals who previously completed a primary series. Propensity score adjustments were conducted to address potential confounding. The analysis included 1130 participants who received a post–primary series dose of NVX-CoV2373 (n = 303) or an mRNA vaccine (n = 827) during the study period. Within the first 2 days after vaccination, solicited systemic reactogenicity events (adjusted) were reported in 60.5% of participants who received NVX-CoV2373 compared with 84.3% of participants who received an mRNA vaccine; moreover, 33.9% and 61.4%, respectively, reported ≥3 systemic reactogenicity symptoms. The adjusted mean (95% CI) number of systemic symptoms was 1.8 (1.6–2.0) and 3.2 (3.0–3.4), respectively. Local reactogenicity events (adjusted) were reported in 73.4% and 91.7% of participants who received NVX-CoV2373 and mRNA vaccines, respectively; the adjusted mean (95% CI) number of local symptoms was 1.5 (1.33–1.61) and 2.4 (2.31–2.52), respectively. These results support the use of adjuvanted, protein-based NVX-CoV2373 as an immunization option with low reactogenicity.

show abstract